Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Hertel, Peter
Nomikos, George G.
and
Svensson, Torgny H.
1997.
Risperidone inhibits 5‐hydroxytryptaminergic neuronal activity in the dorsal raphe nucleus by local release of 5‐hydroxytryptamine.
British Journal of Pharmacology,
Vol. 122,
Issue. 8,
p.
1639.
Nutt, D.J.
Lalies, M.D.
Lione, L.A.
and
Hudson, A.L.
1997.
Noradrenergic mechanisms in the prefrontal cortex.
Journal of Psychopharmacology,
Vol. 11,
Issue. 2,
p.
163.
Schmidt, Mark E.
Risinger, Robert C.
Hauger, Richard L.
Schouten, Jennifer L.
Henry, Michael
and
Potter, William Z.
1997.
Responses to α2-adrenoceptor blockade by idazoxan in healthy male and female volunteers.
Psychoneuroendocrinology,
Vol. 22,
Issue. 3,
p.
177.
Reynolds, Gavin P
1997.
Schizophrenia - advances in drug therapy.
Expert Opinion on Investigational Drugs,
Vol. 6,
Issue. 7,
p.
857.
Reynolds, Gavin P.
1997.
What is an atypical antipsychotic?.
Journal of Psychopharmacology,
Vol. 11,
Issue. 3,
p.
195.
Feng, Jinong
Sobell, Janet L.
Heston, Leonard L.
Goldman, David
Cook, Edwin
Kranzler, Henry R.
Gelernter, Joel
and
Sommer, Steve S.
1998.
Variants in the ?2A AR adrenergic receptor gene in psychiatric patients.
American Journal of Medical Genetics,
Vol. 81,
Issue. 5,
p.
405.
Blake, Tracey-Jane
Tillery, Claire E.
and
Reynolds, Gavin P.
1998.
Antipsychotic drug affinities at α2-adrenoceptor subtypes in post-mortem human brain.
Journal of Psychopharmacology,
Vol. 12,
Issue. 2,
p.
151.
Reynolds, GP
1998.
Receptor mechanisms of antipsychotic drug atypicality.
European Psychiatry,
Vol. 13,
Issue. S1,
p.
5s.
Rowley, Helen L.
Kilpatrick, Ian C.
L. Needham, Patricia
and
Heal, David J.
1998.
Elevation of extracellular cortical noradrenaline may contribute to the antidepressant activity of zotepine: an in vivo microdialysis study in freely moving rats.
Neuropharmacology,
Vol. 37,
Issue. 7,
p.
937.
Hertel, Peter
Lindblom, Nina
Nomikos, George G.
and
Svensson, Torgny H.
1998.
Modulation of central serotonergic neurotransmission by risperidone: Underlying mechanism(s) and significance of action.
Progress in Neuro-Psychopharmacology and Biological Psychiatry,
Vol. 22,
Issue. 5,
p.
815.
Blin, Olivier
1999.
A Comparative Review of New Antipsychotics.
The Canadian Journal of Psychiatry,
Vol. 44,
Issue. 3,
p.
235.
Hertel, Peter
Fagerquist, Maria V.
and
Svensson, Torgny H.
1999.
Enhanced Cortical Dopamine Output and Antipsychotic-like Effects of Raclopride by α
2
Adrenoceptor Blockade
.
Science,
Vol. 286,
Issue. 5437,
p.
105.
See, Ronald E
Fido, Abdullahi A
Maurice, Majed
Ibrahim, Mustafa M
and
Salama, Gamal M.S
1999.
Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia.
Biological Psychiatry,
Vol. 45,
Issue. 12,
p.
1653.
Hertel, Peter
Nomikos, George G
and
Svensson, Torgny H
1999.
Idazoxan preferentially increases dopamine output in the rat medial prefrontal cortex at the nerve terminal level.
European Journal of Pharmacology,
Vol. 371,
Issue. 2-3,
p.
153.
Hertel, Peter
Nomikos, George G.
and
Svensson, Torgny H.
1999.
The antipsychotic drug risperidone interacts with auto- and hetero-receptors regulating serotonin output in the rat frontal cortex.
Neuropharmacology,
Vol. 38,
Issue. 8,
p.
1175.
Wahlbeck, Kristian
Cheine, Maxim V
Essali, Adib
and
Wahlbeck, Kristian
1999.
Cochrane Database of Systematic Reviews.
Krystal, John H
D'Souza, D.Cyril
Madonick, Steven
and
Petrakis, Ismene L
1999.
Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients.
Schizophrenia Research,
Vol. 35,
Issue. ,
p.
S35.
Aman, Michael G.
and
Madrid, Annette
1999.
Atypical antipsychotics in persons with developmental disabilities.
Mental Retardation and Developmental Disabilities Research Reviews,
Vol. 5,
Issue. 4,
p.
253.
Bolonna, A.A
Arranz, M.J
Munro, J
Osborne, S
Petouni, M
Martinez, M
and
Kerwin, R.W
2000.
No influence of adrenergic receptor polymorphisms on schizophrenia and antipsychotic response.
Neuroscience Letters,
Vol. 280,
Issue. 1,
p.
65.
Millan, Mark J.
Gobert, Alain
Newman-Tancredi, Adrian
Lejeune, Françoise
Cussac, Didier
Rivet, Jean-Michel
Audinot, Valérie
Adhumeau, Agnès
Brocco, Mauricette
Nicolas, Jean-Paul
Boutin, Jean A.
Despaux, Nicole
and
Peglion, Jean-Louis
2000.
S18327 (1-{2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl}3-phenyl imidazolin-2-one), a Novel, Potential Antipsychotic Displaying Marked Antagonist Properties at α1- and α2-Adrenergic Receptors: I. Receptorial, Neurochemical, and Electrophysiological Profile.
The Journal of Pharmacology and Experimental Therapeutics,
Vol. 292,
Issue. 1,
p.
38.
eLetters
No eLetters have been published for this article.